Clinical assessment of treatments for prolonged bleeding in users of norplantR implants

Soledad Dĺaz, Horacio B. Croxatto, Margarita Pavez, Hedia Belhadj, Janet Stern, Irving Sivin

Resultado de la investigación: Article

72 Citas (Scopus)

Resumen

The effectiveness of three drugs in controlling prolonged bleeding in the first year of NORPLANTR implants use was tested. The drugs were levonorgestrel (L-Ng, 0.03 mg twice a day for 20 days), ethinylestradiol (EE, 0.05 mg per day for 20 days) and ibuprofen (Ib, 800 mg three times a day for 5 days) and were given orally. A control group received a placebo (PL, one pill of lactose for 20 days). Treatment should start each time a woman experienced eight consecutive days of bleeding or spotting. The 183 volunteers were not aware of the drug administered. A daily record of bleeding and spotting and of treatment intake was maintained. One-hundred-forty women completed the study period; 60 never used the prescribed treatment. Women treated with the three test drugs had significantly fewer bleeding and spotting days during the treated month and also throughout the study year than women using the placebo. The mean number of bleeding plus spotting days per actually treated subject in the first year was 77, 94, 101 and 129 days for the EE, Ib, L-Ng and PL groups, respectively. The administration of EE might help in the management of prolonged bleeding during the first year of NORPLANTR implants use.

Idioma originalEnglish
Páginas (desde-hasta)97-109
Número de páginas13
PublicaciónContraception
Volumen42
N.º1
DOI
EstadoPublished - 1 ene 1990

Huella dactilar

Metrorrhagia
Hemorrhage
Pharmaceutical Preparations
Therapeutics
Placebos
Levonorgestrel
Ethinyl Estradiol
Ibuprofen
Lactose
Volunteers
Control Groups

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynaecology

Citar esto

Dĺaz, Soledad ; Croxatto, Horacio B. ; Pavez, Margarita ; Belhadj, Hedia ; Stern, Janet ; Sivin, Irving. / Clinical assessment of treatments for prolonged bleeding in users of norplantR implants. En: Contraception. 1990 ; Vol. 42, N.º 1. pp. 97-109.
@article{d34f826082f747bf9d8b89fee296bcc7,
title = "Clinical assessment of treatments for prolonged bleeding in users of norplantR implants",
abstract = "The effectiveness of three drugs in controlling prolonged bleeding in the first year of NORPLANTR implants use was tested. The drugs were levonorgestrel (L-Ng, 0.03 mg twice a day for 20 days), ethinylestradiol (EE, 0.05 mg per day for 20 days) and ibuprofen (Ib, 800 mg three times a day for 5 days) and were given orally. A control group received a placebo (PL, one pill of lactose for 20 days). Treatment should start each time a woman experienced eight consecutive days of bleeding or spotting. The 183 volunteers were not aware of the drug administered. A daily record of bleeding and spotting and of treatment intake was maintained. One-hundred-forty women completed the study period; 60 never used the prescribed treatment. Women treated with the three test drugs had significantly fewer bleeding and spotting days during the treated month and also throughout the study year than women using the placebo. The mean number of bleeding plus spotting days per actually treated subject in the first year was 77, 94, 101 and 129 days for the EE, Ib, L-Ng and PL groups, respectively. The administration of EE might help in the management of prolonged bleeding during the first year of NORPLANTR implants use.",
author = "Soledad Dĺaz and Croxatto, {Horacio B.} and Margarita Pavez and Hedia Belhadj and Janet Stern and Irving Sivin",
year = "1990",
month = "1",
day = "1",
doi = "10.1016/0010-7824(90)90094-C",
language = "English",
volume = "42",
pages = "97--109",
journal = "Contraception",
issn = "0010-7824",
publisher = "Elsevier USA",
number = "1",

}

Clinical assessment of treatments for prolonged bleeding in users of norplantR implants. / Dĺaz, Soledad; Croxatto, Horacio B.; Pavez, Margarita; Belhadj, Hedia; Stern, Janet; Sivin, Irving.

En: Contraception, Vol. 42, N.º 1, 01.01.1990, p. 97-109.

Resultado de la investigación: Article

TY - JOUR

T1 - Clinical assessment of treatments for prolonged bleeding in users of norplantR implants

AU - Dĺaz, Soledad

AU - Croxatto, Horacio B.

AU - Pavez, Margarita

AU - Belhadj, Hedia

AU - Stern, Janet

AU - Sivin, Irving

PY - 1990/1/1

Y1 - 1990/1/1

N2 - The effectiveness of three drugs in controlling prolonged bleeding in the first year of NORPLANTR implants use was tested. The drugs were levonorgestrel (L-Ng, 0.03 mg twice a day for 20 days), ethinylestradiol (EE, 0.05 mg per day for 20 days) and ibuprofen (Ib, 800 mg three times a day for 5 days) and were given orally. A control group received a placebo (PL, one pill of lactose for 20 days). Treatment should start each time a woman experienced eight consecutive days of bleeding or spotting. The 183 volunteers were not aware of the drug administered. A daily record of bleeding and spotting and of treatment intake was maintained. One-hundred-forty women completed the study period; 60 never used the prescribed treatment. Women treated with the three test drugs had significantly fewer bleeding and spotting days during the treated month and also throughout the study year than women using the placebo. The mean number of bleeding plus spotting days per actually treated subject in the first year was 77, 94, 101 and 129 days for the EE, Ib, L-Ng and PL groups, respectively. The administration of EE might help in the management of prolonged bleeding during the first year of NORPLANTR implants use.

AB - The effectiveness of three drugs in controlling prolonged bleeding in the first year of NORPLANTR implants use was tested. The drugs were levonorgestrel (L-Ng, 0.03 mg twice a day for 20 days), ethinylestradiol (EE, 0.05 mg per day for 20 days) and ibuprofen (Ib, 800 mg three times a day for 5 days) and were given orally. A control group received a placebo (PL, one pill of lactose for 20 days). Treatment should start each time a woman experienced eight consecutive days of bleeding or spotting. The 183 volunteers were not aware of the drug administered. A daily record of bleeding and spotting and of treatment intake was maintained. One-hundred-forty women completed the study period; 60 never used the prescribed treatment. Women treated with the three test drugs had significantly fewer bleeding and spotting days during the treated month and also throughout the study year than women using the placebo. The mean number of bleeding plus spotting days per actually treated subject in the first year was 77, 94, 101 and 129 days for the EE, Ib, L-Ng and PL groups, respectively. The administration of EE might help in the management of prolonged bleeding during the first year of NORPLANTR implants use.

UR - http://www.scopus.com/inward/record.url?scp=0025286256&partnerID=8YFLogxK

U2 - 10.1016/0010-7824(90)90094-C

DO - 10.1016/0010-7824(90)90094-C

M3 - Article

C2 - 2117517

AN - SCOPUS:0025286256

VL - 42

SP - 97

EP - 109

JO - Contraception

JF - Contraception

SN - 0010-7824

IS - 1

ER -